Voyager Therapeutics Announces Planned Transition Process for Chief Financial Officer
October 18 2016 - 4:05PM
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene
therapy company developing life-changing treatments for severe
diseases of the central nervous system (CNS), today announced a
transition process for Jeff Goater, Voyager’s chief financial
officer, who has advised the Company of his plans to pursue other
career opportunities. As the Company initiates a search for
this role, Jeff will remain in his current position until January
2017, after which time he has agreed to serve as a consultant to
the Company.
“Jeff has done an extraordinary job since
joining our company more than three years ago as one of our first
employees and it has been a great pleasure working closely with
him,” said Steve Paul, M.D., president and chief executive officer
of Voyager. “Jeff played a major role transitioning Voyager
from a private to a public company, facilitating the advancement of
our clinical and preclinical programs. On behalf of the Board
and the rest of our leadership team here at Voyager, we thank him
for his service and wish him success in his next endeavor.”
“Voyager truly has been an incredible
opportunity and rewarding experience for me and it has been a
pleasure to work along side such a talented and dedicated group,”
said Mr. Goater. “I look forward to continuing to work with
the Company to ensure a seamless and smooth transition of my
duties.”
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene
therapy company developing life-changing treatments for severe
diseases of the CNS. Voyager is committed to advancing the
field of AAV (adeno-associated virus) gene therapy through
innovation and investment in vector engineering and optimization,
manufacturing and dosing and delivery techniques. The
Company’s pipeline is focused on severe CNS diseases in need of
effective new therapies, including advanced Parkinson’s disease, a
monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s
ataxia, Huntington’s disease, spinal muscular atrophy (SMA),
frontotemporal dementia, Alzheimer’s disease and severe, chronic
pain. Voyager has broad strategic collaborations with Sanofi
Genzyme, the specialty care global business unit of Sanofi, and the
University of Massachusetts Medical School. Founded by
scientific and clinical leaders in the fields of AAV gene therapy,
expressed RNA interference and neuroscience, Voyager Therapeutics
is headquartered in Cambridge, Massachusetts. For more
information, please visit www.voyagertherapeutics.com. Follow
Voyager on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities law. The use of words such as “may,” “might,” “will,”
“should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“project,” “intend,” “future,” “potential,” or “continue,” and
other similar expressions are intended to identify forward-looking
statements. For example, all statements Voyager makes
regarding the initiation, timing, progress and reporting of results
of its preclinical programs and clinical trials and its research
and development programs, its ability to advance its AAV-based gene
therapies into, and successfully complete, clinical trials, its
ability to continue to develop its product engine, its ability to
add new programs to its pipeline, its expected cash, cash
equivalents and marketable securities at the end of a fiscal year
and anticipation for how long expected cash, cash equivalents and
marketable securities will last, and the timing or likelihood of
its regulatory filings and approvals, are forward looking.
All forward-looking statements are based on estimates and
assumptions by Voyager’s management that, although Voyager believes
to be reasonable, are inherently uncertain. All
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those that
Voyager expected. These statements are also subject to a
number of material risks and uncertainties that are described in
Voyager’s most recent Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission, as updated by its future
filings with the Securities and Exchange Commission. Any
forward-looking statement speaks only as of the date on which it
was made. Voyager undertakes no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
law.
Investor Relations:
Matt Osborne
Head of Investor Relations & Corporate Communications
857-259-5353
mosborne@vygr.com
Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Apr 2024 to May 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From May 2023 to May 2024